Stand Up for Research!

Tags

, , ,

Gianna RendanoGianna Rendano is the administrative and development coordinator at Americans for Medical Progress. She received her B.A. from Duquesne University where she majored in international relations and concentrated on humanitarian operations.

As has been their tradition for over three decades, animal rights activists are gathering in several cities the third week in April to mark their World Week for Animals in Laboratories observance. Their concern for the welfare of the animals is to be commended— it is shared by most who work in America’s research institutions. However, the activists’ lurid descriptions of researchers as mad scientists and their insistent calls for the immediate end of animal-based studies are entirely misplaced. Continue reading

Liquid Salt as Green Solvents

Tags

, , ,

Retush Dave Anant Patel Anant Patel is a Ph.D. candidate at Arnold and Marie Schwartz College of Pharmacy and Health Sciences at Long Island University. He is skilled in formulation and characterization of small molecules and equally interested in other branches of pharmaceutical sciences. Rutesh H. Dave, Ph.D., is currently Division Director of Pharmaceutical Sciences at Arnold and Marie Schwartz College of Pharmacy and Health Sciences at Long Island University. His current interests are in the field of preformulation, formulation and drug delivery.

According to leading market research, the global oral drug delivery market share in 2010 was valued at $49 billion and expected to grow to $97 billion by 2017. Success of the oral drug formulations relies on the aqueous solubility and intestinal permeability of drug molecules, which govern oral absorption. Despite increased demand for oral formulations, nowadays, most new drug molecules discovered are poorly soluble and/or have low permeability, which are major obstacles in oral formulations development. Continue reading

Spring Break 2014: AAPS Blog Edition

Tags

,

The AAPS Blog is on spring break this week, recharging our batteries at an undisclosed location.

We will return on April 22, and that week will include posts related to Earth Day, World Laboratory Animal Liberation Week, and the May AAPS Newsmagazine cover story. So please visit us then!

Meanwhile, if you have suggestions for blog topics or if you want to contribute to the blog, please contact us at aapsblog@aaps.org.

shutterstock_131233523

The Expanding Universe of the CRO

Tags

, ,

John KamerudJohn Q. Kamerud, Ph.D., is scientific director at Eurofins Pharma Bioanalytical Services, where he serves as scientific and technical advisor for both clients and internal teams for development, validation, and application of assays to comply with scientific goals and regulatory requirements. He has over 20 years of experience in the development, validation, and implementation of immunoassay methods.

The past few years have seen a tremendous amount of restructuring, integration, and “right-sizing” within our industry. According to Forbes, pharma companies have laid off more than 300,000 workers since 2000. A substantial proportion of these were in research and development (R&D) functions. Does that mean that drug development has come to a standstill? Hardly. According to FiercePharma, global R&D spending in the pharma industry increased approximately 228% in the decade 2000–2010. Much of that slack is being taken up by CROs (contract research organizations), which saw a doubling in employment during the same decade, according to the Center for the Study of Drug Development at Tufts University.

Continue reading

Is Social Media the Modern-Day Way to Gain Access to Experimental Drugs?

Tags

, , , , ,

Karen AddisKaren Addis, APR, is senior vice president at Van Eperen & Company, a full-service public relations and marketing communications agency in the Washington, D.C., area, where she specializes in healthcare communications. You can contact her at kaddis@veandco.com.You can also follow her on Twitter or connect with her on LinkedIn.

Until a few weeks ago, few people outside of the small town of Fredericksburg, Va., had heard of Josh Hardy, a 7-year-old who had been suffering from various forms of cancer since he was nine months old.

But all that changed in early March when his mom used social media to draw public attention to her son’s story, which recently had taken a turn for the worse. Josh had been in the hospital recovering from a bone marrow transplant when he developed a serious infection. He most likely was going to die if he did not receive the experimental drug brincidofovir, which had been shown in clinical trials to clear up adenovirus infections in children.

Continue reading

Follow

Get every new post delivered to your Inbox.

Join 144 other followers